Mississauga is set to benefit from a significant economic boost as AstraZeneca Canada announces the creation of 700 new jobs through a major expansion of its research and development (R&D) facilities.
On Thursday, government officials and company leaders gathered to reveal details of a $16.1 million investment from the Invest Ontario Fund to support AstraZeneca’s $820 million plan to expand its footprint in Mississauga and relocate its Canadian headquarters to a larger, state-of-the-art facility.
“AstraZeneca’s investment is fantastic news for Ontario and a testament to the remarkable talent, innovation, and opportunities our province offers,” said Ontario Premier Doug Ford during the announcement. “We are proud to support this expansion, which will create hundreds of highly skilled jobs and further solidify Ontario’s position as a global leader in life sciences and innovation.”
The expanded R&D Hub will focus on clinical studies in key areas such as breast, lung, and prostate cancer, COVID-19, and chronic kidney disease, alongside rare disease research. AstraZeneca first announced its plans for a rare disease research hub in 2023, which included the creation of 500 new scientific roles.
With the latest expansion, AstraZeneca’s total investment in Ontario now exceeds $1.3 billion, adding more than 1,200 high-value jobs across both projects.
The Mississauga facility already serves as a strategic global clinical hub for AstraZeneca, employing 1,500 people and leading over 210 global clinical studies.
This latest investment will enable AstraZeneca to further integrate digital health technologies, artificial intelligence (AI), and computational pathology into clinical trial designs, advancing treatments for cancer, infectious diseases, and rare illnesses.
“AstraZeneca’s continued investment in Ontario is crucial to advancing innovative medicines that treat, prevent, and may one day cure complex diseases,” said Gaby Bourbara, president of AstraZeneca Canada. “Collaborations like today’s reflect our shared commitment to driving economic growth, fostering innovation, and improving outcomes for patients globally.”
The expansion will solidify Ontario’s standing as a global hub for life sciences and biomanufacturing. In addition to creating hundreds of jobs, it supports the province’s efforts to lead in the development, commercialization, and early adoption of innovative health products and services.
AstraZeneca’s cutting-edge technologies will contribute to the global fight against diseases while ensuring Mississauga remains at the forefront of scientific discovery.
With over 700 new jobs created as part of the expansion, Mississauga is poised to see continued economic growth and innovation in the life sciences sector, further enhancing the city’s reputation as a center for groundbreaking research and development.